Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia
S Anguille, AL Van de Velde, EL Smits… - Blood, The Journal …, 2017 - ashpublications.org
Relapse is a major problem in acute myeloid leukemia (AML) and adversely affects survival.
In this phase 2 study, we investigated the effect of vaccination with dendritic cells (DCs) …
In this phase 2 study, we investigated the effect of vaccination with dendritic cells (DCs) …
ATP release from chemotherapy-treated dying leukemia cells elicits an immune suppressive effect by increasing regulatory T cells and tolerogenic dendritic cells
M Lecciso, D Ocadlikova, S Sangaletti… - Frontiers in …, 2017 - frontiersin.org
Chemotherapy-induced immunogenic cell death can favor dendritic cell (DC) cross-priming
of tumor-associated antigens for T cell activation thanks to the release of damage …
of tumor-associated antigens for T cell activation thanks to the release of damage …
Immunopeptidomics-guided warehouse design for peptide-based immunotherapy in chronic lymphocytic leukemia
Antigen-specific immunotherapies, in particular peptide vaccines, depend on the recognition
of naturally presented antigens derived from mutated and unmutated gene products on …
of naturally presented antigens derived from mutated and unmutated gene products on …
The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy
Antileukemia immunity plays an important role in disease control and maintenance of
tyrosine kinase inhibitor (TKI)-free remission in chronic myeloid leukemia (CML). Thus …
tyrosine kinase inhibitor (TKI)-free remission in chronic myeloid leukemia (CML). Thus …
[HTML][HTML] Reversal of T cell exhaustion by the first donor lymphocyte infusion is associated with the persistently effective antileukemic responses in patients with …
L Liu, YJ Chang, LP Xu, XH Zhang, Y Wang… - Biology of Blood and …, 2018 - Elsevier
Donor lymphocyte infusion (DLI) is an effective approach to treat acute myelogenous
leukemia (AML) relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) …
leukemia (AML) relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) …
Monocytes reprogrammed with lentiviral vectors co-expressing GM-CSF, IFN-α2 and antigens for personalized immune therapy of acute leukemia pre-or post-stem …
JK Bialek-Waldmann, M Heuser, A Ganser… - Cancer Immunology …, 2019 - Springer
Acute myeloid leukemia (AML) is the most common acute leukemia in adults and overall
survival remains poor. Chemotherapy is the standard of care for intensive induction therapy …
survival remains poor. Chemotherapy is the standard of care for intensive induction therapy …
Wilms' tumor 1 gene in hematopoietic malignancies: Clinical implications and future directions
P Luo, W Jing, K Yi, S Wu, F Zhou - Leukemia & Lymphoma, 2020 - Taylor & Francis
Abstract The Wilms' tumor 1 (WT1) gene is an important regulatory molecule that plays a
vital role in cell growth and development. Initially, knowledge of WT1 was mostly limited to …
vital role in cell growth and development. Initially, knowledge of WT1 was mostly limited to …
[HTML][HTML] Wilms tumor 1 expression and pre-emptive immunotherapy in patients with acute myeloid leukemia undergoing an allogeneic hemopoietic stem cell …
C Di Grazia, S Pozzi, S Geroldi, R Grasso… - Biology of Blood and …, 2016 - Elsevier
Minimal residual disease (MRD) was monitored by Wilms tumor 1 (WT1) expression in 207
patients with acute myeloid leukemia (AML) after an allogeneic hemopoietic stem cell …
patients with acute myeloid leukemia (AML) after an allogeneic hemopoietic stem cell …
HLA-DR presentation of the tumor antigen MSLN associates with clinical outcome of ovarian cancer patients
Simple Summary The immunopeptidome represents the entirety of peptides that are
presented on the surface of cells on human leukocyte antigen (HLA) molecules and are …
presented on the surface of cells on human leukocyte antigen (HLA) molecules and are …
Peripheral blood marker of residual acute leukemia after hematopoietic cell transplantation using multi-plex digital droplet PCR
M Stanojevic, M Grant, SK Vesely, S Knoblach… - Frontiers in …, 2022 - frontiersin.org
Background Relapse remains the primary cause of death after hematopoietic cell
transplantation (HCT) for acute leukemia. The ability to identify minimal/measurable residual …
transplantation (HCT) for acute leukemia. The ability to identify minimal/measurable residual …